Q3 revenue and profit declined sharply year-over-year, mainly due to weak pharmaceutical and diagnostic sales, while core cardiovascular and anesthesia businesses grew. Restructuring and R&D costs pressured margins, but new product approvals and a cash dividend were notable positives.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.